Financials Medpace Holdings, Inc.

Equities

MEDP

US58506Q1094

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 24/05/2024 BST 5-day change 1st Jan Change
390.6 USD -0.01% Intraday chart for Medpace Holdings, Inc. -0.70% +27.41%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,010 4,952 7,782 6,589 9,405 12,073 - -
Enterprise Value (EV) 1 2,878 4,674 7,320 6,749 9,302 11,359 11,022 10,603
P/E ratio 31.5 x 36.3 x 45.2 x 29.2 x 34.5 x 34.8 x 29.8 x 25.3 x
Yield - - - - - - - -
Capitalization / Revenue 3.5 x 5.35 x 6.81 x 4.51 x 4.99 x 5.57 x 4.79 x 4.18 x
EV / Revenue 3.34 x 5.05 x 6.41 x 4.62 x 4.93 x 5.24 x 4.38 x 3.67 x
EV / EBITDA 19.2 x 24.9 x 32.8 x 21.9 x 25.7 x 26.3 x 21.8 x 18 x
EV / FCF 15.6 x 20.6 x 31.1 x 19.2 x 23.4 x 24.5 x 23.5 x 21.3 x
FCF Yield 6.39% 4.86% 3.21% 5.2% 4.26% 4.09% 4.25% 4.7%
Price to Book 4.35 x 6.51 x 8.61 x 18.5 x 17.5 x 13 x 10.1 x 7.81 x
Nbr of stocks (in thousands) 35,812 35,572 35,754 31,018 30,683 30,913 - -
Reference price 2 84.06 139.2 217.6 212.4 306.5 390.6 390.6 390.6
Announcement Date 24/02/20 15/02/21 14/02/22 13/02/23 12/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 861 925.9 1,142 1,460 1,886 2,169 2,519 2,886
EBITDA 1 149.6 187.8 223.1 308.1 362.5 431.6 504.6 587.7
EBIT 1 141.2 176.1 207.1 285.8 338.4 399.7 471.7 552.2
Operating Margin 16.4% 19.02% 18.13% 19.57% 17.94% 18.43% 18.73% 19.13%
Earnings before Tax (EBT) 1 124.8 168.5 201.9 282.9 335.7 426 502.6 588.2
Net income 1 100.4 145.4 181.8 245.4 282.8 359.9 419.9 491.7
Net margin 11.67% 15.7% 15.92% 16.81% 15% 16.59% 16.67% 17.04%
EPS 2 2.670 3.840 4.810 7.280 8.880 11.21 13.09 15.46
Free Cash Flow 1 184 227.3 235.1 351.2 396.7 464.1 468.5 498.8
FCF margin 21.37% 24.55% 20.58% 24.05% 21.04% 21.4% 18.6% 17.28%
FCF Conversion (EBITDA) 122.97% 121.08% 105.37% 113.98% 109.44% 107.55% 92.84% 84.88%
FCF Conversion (Net income) 183.14% 156.37% 129.26% 143.12% 140.28% 128.97% 111.58% 101.45%
Dividend per Share 2 - - - - - - - -
Announcement Date 24/02/20 15/02/21 14/02/22 13/02/23 12/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 308.6 330.9 351.2 383.7 394.1 434.1 460.9 492.5 498.4 511 528.8 554.8 572.3 594.7 619.4
EBITDA 1 61.41 70.38 68.09 89.26 80.37 92.85 83.63 90.18 95.84 115.7 101.1 105.9 110.2 123.2 119.7
EBIT 1 57.22 66.11 63.38 84.31 74.47 87.44 77.66 83.86 89.41 109 94.19 99.15 102.8 113.1 112.2
Operating Margin 18.55% 19.98% 18.05% 21.97% 18.9% 20.14% 16.85% 17.03% 17.94% 21.33% 17.81% 17.87% 17.96% 19.02% 18.12%
Earnings before Tax (EBT) 1 55.92 65.32 62 81.89 73.64 86.03 75.74 83.2 90.71 112.8 99.33 105.1 109.8 120.1 118.7
Net income 1 50.03 61.31 49.36 66.03 68.67 72.89 61.07 70.55 78.3 102.6 81.88 86.64 90.51 100 98.93
Net margin 16.22% 18.53% 14.05% 17.21% 17.42% 16.79% 13.25% 14.32% 15.71% 20.07% 15.48% 15.62% 15.81% 16.82% 15.97%
EPS 2 1.320 1.690 1.460 2.050 2.120 2.270 1.930 2.220 2.460 3.200 2.530 2.687 2.814 3.187 3.082
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 14/02/22 25/04/22 25/07/22 24/10/22 13/02/23 24/04/23 24/07/23 23/10/23 12/02/24 22/04/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - 161 - - - -
Net Cash position 1 132 278 461 - 103 715 1,051 1,470
Leverage (Debt/EBITDA) - - - 0.5213 x - - - -
Free Cash Flow 1 184 227 235 351 397 464 468 499
ROE (net income / shareholders' equity) 17.2% 19.9% 20.7% 36.6% 59.8% 45.7% 37.1% 35.5%
ROA (Net income/ Total Assets) 10.7% - 11.9% 16.3% 18.8% 18.2% 16.5% 15.5%
Assets 1 935.7 - 1,525 1,506 1,505 1,976 2,543 3,176
Book Value Per Share 2 19.30 21.40 25.30 11.50 17.60 30.10 38.70 50.00
Cash Flow per Share 2 5.370 6.860 6.990 11.50 13.60 16.70 15.80 18.00
Capex 1 17.9 31.3 28.3 36.9 36.6 47.1 56.4 63.7
Capex / Sales 2.08% 3.38% 2.47% 2.53% 1.94% 2.17% 2.24% 2.21%
Announcement Date 24/02/20 15/02/21 14/02/22 13/02/23 12/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
390.6 USD
Average target price
423.2 USD
Spread / Average Target
+8.35%
Consensus
  1. Stock Market
  2. Equities
  3. MEDP Stock
  4. Financials Medpace Holdings, Inc.